TLDR
- On October 5, 2026, ARK Invest divested 90,713 shares of Twist Bioscience valued at approximately $17.1 million.
- The investment firm acquired 1,482,357 shares of Recursion Pharmaceuticals for roughly $6.1 million.
- ARK purchased 96,308 Intellia Therapeutics shares at a cost of approximately $1.18 million.
- An additional 115,472 Veracyte shares were acquired for around $5.29 million, while positions in 10x Genomics and CareDx were reduced.
- Recursion’s stock climbed over 16% Monday; Intellia awaits a critical FDA ruling scheduled for March 10, 2027.
Cathie Wood’s [[LINK_START_1]]ARK Invest[[LINK_END_1]] executed a series of portfolio adjustments throughout its exchange-traded fund lineup on Monday, October 5, 2026. Transaction details were disclosed by the firm the following morning.
The investment management company divested 90,713 shares of Twist Bioscience across its ARKK and ARKG funds, representing a transaction value of approximately $17.1 million.
This divestment marks ARK’s second sale of Twist Bioscience holdings this month. Previously, the firm offloaded 46,931 shares of the biotechnology company on September 29.
ARK’s New Acquisitions
The firm accumulated 1,482,357 shares of Recursion Pharmaceuticals during Monday’s trading session. This acquisition, valued at roughly $6.1 million, was executed through both the ARKK and ARKG funds.
Recursion Pharmaceuticals, Inc., RXRX
Recursion operates as a biotechnology firm leveraging artificial intelligence technologies for pharmaceutical discovery. The company’s stock experienced significant upward momentum, climbing more than 16% during Monday’s session.
The biotech firm recently announced an extension of its data-licensing partnership with Tempus, now running through 2029. Market analysts have established a consensus 12-month price objective of $7.22 for the equity, based on Koyfin data.
ARK’s trading activity also included the purchase of 96,308 Intellia Therapeutics shares, amounting to approximately $1.18 million in value.
This transaction represents a continuation of recent buying activity. Since September 29, ARK has accumulated over 1,178,000 Intellia shares.
Intellia currently awaits a regulatory determination from the FDA regarding its primary therapeutic candidate, designed to treat hereditary angioedema. The agency’s decision deadline is scheduled for March 10, 2027.
Financial institution Barclays recently initiated research coverage on Intellia with an “Underweight” designation. The investment bank established a price objective of $8, implying a potential 36% decline from present trading levels.
Additionally, ARK acquired 115,472 Veracyte shares exclusively through its ARKG fund, representing a transaction value of approximately $5.29 million.
Veracyte recently disclosed positive Phase 3 clinical trial results. The findings demonstrated that the company’s Decipher Prostate diagnostic test can effectively identify prostate cancer patients likely to derive enhanced benefit from combining hormone therapy with radiation treatment protocols.
ARK’s Portfolio Reductions
In addition to the Twist Bioscience divestment, ARK reduced holdings in two additional biotechnology companies on Monday.
The investment firm sold 27,277 shares of 10x Genomics, representing approximately $2.55 million in transaction value.
ARK also liquidated 22,271 CareDx shares in a sale valued at roughly $1.5 million.
Twist Bioscience stock appreciated 8.7% during Monday trading. The equity has surged more than 60% throughout the preceding month.
Market observers attribute the stock’s momentum to investor enthusiasm surrounding the company’s synthetic-DNA technology platform. Twist has also established a collaborative arrangement supporting Eli Lilly’s TuneLab AI-powered drug-discovery infrastructure.
10x Genomics shares climbed 4.5% Monday and have advanced more than 48% over the past month. CareDx stock rose 4% during the session, achieving its highest valuation in over four years.
Throughout recent weeks, ARK has divested approximately $6 million worth of Twist Bioscience holdings via its ARKG fund. The firm maintains its practice of publishing daily transaction data each morning.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
